Year: 2026
Type: article
Abstract: To the Editor:Dengue, a significant global health threat, currently lacks effective antiviral treatments. 1 Mosnodenvir is an antiviral against dengue virus (DENV) infection which has reached phase 2 clinical development in a prophylactic setting. 2 Initial results from this randomized, double-blind, placebo-controlled Phase 2a trial (Cohort 1[C1]) have been published 1 and were expanded with additional daily (QD) and weekly (Q7D) dose regimens in Cohort 2 (C2).Loading doses (LD) started on Day (D) -2 twice daily (BID) for 2 days, followed by maintenance doses (MD) as QD or Q7D for 21 days (QD, 800 mg/250 mg, Q7D high-dose 450 mg/1200 mg and low-dose 250 mg/500 mg).The under-attenuated virus rDEN3Δ30 was subcutaneously injected on D1 with safety, pharmacokinetics, virology and serology parameters evaluated up to D120 (Figure 1A).The protocol and Supplementary Appendix are available with the full text of this letter at NEJM.org.
Source: New England Journal of Medicine
DOI: 10.1056/nejmc2516395
Authors: Liesbeth Van Wesenbeeck, Freya Rasschaert, Kristen K. Pierce, Guillermo Herrera-Taracena, Beulah P. Sabundayo, Annemie Buelens, Patricia Lutton, Veerle Van Eygen, Megan McKnight, Kim De Clerck, Isabel Fetter, Xi Fang, Nele Goeyvaerts, Kathleen Callewaert, Sarah Sampson, Jeffrey Mayfield, Oliver Lenz, Sandra De Meyer, Thomas N. Kakuda, Helen He, Emérito Amaro-Carambot, Ruxandra Draghia-Akli, Marya Carmolli, Marnix Van Loock, Stephen S. Whitehead, Anna P. Durbin
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Award: G9001280887
OpenAlex ID: W7221798569